Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.71 |
| ▸ | AURKA | O14965 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2102544 | 1.00 | SYK (0.71) | SYKAURKAEGFR | |
| SCHEMBL2100656 | 0.88 | SYK (0.55) | SYKAURKA | |
| SCHEMBL2104254 | 0.86 | BCL6 (0.58) | SYKEGFR | |
| SCHEMBL2104279 | 0.84 | SYK (0.50) | SYKAURKAEGFR | |
| SCHEMBL2100651 | 0.84 | SYK (0.50) | SYKAURKAEGFR | |
| SCHEMBL656736 | 0.83 | SYK (1.00) | SYKAURKAEGFR | |
| SCHEMBL31294190 | 0.83 | SYK (1.00) | SYKAURKAEGFR | |
| SCHEMBL655683 | 0.83 | SYK (0.71) | SYKAURKAEGFR | |
| SCHEMBL2103251 | 0.81 | SYK (0.72) | SYKEGFR | |
| SCHEMBL2103244 | 0.75 | SYK (0.67) | SYKAURKAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | claimed |
| EP-2130541-A2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | claimed |